Search results for "From ACP Journal Club"
Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk
An ACP Journal Club commentary noted that the mechanism by which liraglutide improves renal outcomes is uncertain and that renal benefit was driven by a decrease in the surrogate outcome of macroalbuminuria, with measures of renal impairment remaining unchanged.
https://diabetes.acponline.org/archives/2018/01/12/9.htm
12 Jan 2018
Two reviews analyze efficacy of newer drug classes in type 1 and type 2 diabetes
The evidence favors glucagon-like peptide 1 agonists and, particularly, sodium–glucose cotransporter 2 inhibitors for type 2 diabetes, but the benefits in type 1 diabetes remain speculative, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/08/10/8.htm
10 Aug 2018
GLP-1 RA plus SGLT-2 inhibitor vs. either drug alone reduces HbA1c and SBP
The finding that combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors improves glycemic control and systolic blood pressure (SBP) without increasing hypoglycemia is important, but additional cost-effectiveness research on the drugs is needed, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/12/11/9.htm
11 Dec 2020
Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death
The review suggests that treating diabetes with strict glycemic control does not reduce mortality or cardiovascular risk or slow progression of kidney disease, and the results question whether strict glycemic control for preventing any complications is warranted, ACP Journal Club authors wrote.
https://diabetes.acponline.org/archives/2017/11/10/8.htm
10 Nov 2017
Review: In diabetes, benefits of lowering BP depend on baseline BP being 140 mm Hg or more
Hypertension treatment reduced mortality and myocardial infarction in diabetic patients with a systolic blood pressure of at least 140 mm Hg, a systematic review and meta-analysis found. However, in patients with lower baseline blood pressure (BP), treatment didn't affect overall mortality and was associated with increased cardiovascular mortality.
https://diabetes.acponline.org/archives/2016/07/15/6.htm
15 Jul 2016
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin
The trial showed that an oral glucagon-like peptide-1–receptor analogue improved glycemic control compared to a dipeptidyl peptidase 4 inhibitor, but gastrointestinal side effects and cost remain barriers to use of the former class.
https://diabetes.acponline.org/archives/2019/09/13/7.htm
13 Sep 2019
In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding
Although an industry-funded trial found little net benefit overall from adding ticagrelor to aspirin, it's possible that some patients with higher ischemic risk and low bleeding risk could benefit, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/02/14/6.htm
14 Feb 2020
In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 years
The results showed that when patients on multiple daily insulin injections received structured education, there was no additional benefit of switching to pump therapy for glycemic control, hypoglycemia rates, or quality of life, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2017/09/08/6.htm
8 Sep 2017
In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis
The study authors concluded that the negative effects observed would limit clinical use of liraglutide in patients with type 1 diabetes.
https://diabetes.acponline.org/archives/2017/01/13/6.htm
13 Jan 2017
In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis
Taking canagliflozin, at a dose of either 100 mg or 300 mg per day, was associated with risk of diabetic ketoacidosis, according to a trial that randomized patients with type 1 diabetes to either of the doses or a placebo.
https://diabetes.acponline.org/archives/2016/08/12/5.htm
12 Aug 2016